- 09/19/2019
- eisai to present latest data on lemborexant at world sleep congress
- 09/18/2019
- fda approves lenvima® (lenvatinib) plus keytruda® (pembrolizumab) combination treatment for patients with certain types of endometrial carcinoma
- 09/18/2019
- eisai selected for membership in dow jones sustainability asia pacific index 2019 for sixth time
- 09/17/2019
- eisai receives iia japan chairman’s award of institute of internal auditors - japan
- 08/28/2019
- eisai enters into business alliance with cogstate for exclusive development and commercialization of a digital tool for self-assessment of cognitive function in japan
- 08/27/2019
- eisai provides tanks to supply clean water to neglected tropical diseases endemic regions in kenya, in collaboration with merck
- 08/07/2019
- eisai china inc. participates in cpc sub-branch co-construction campaign in zhenping
- 07/23/2019
- eisai and merck & co., inc., kenilworth, n.j., u.s.a. receive breakthrough therapy designation from fda for lenvima® (lenvatinib) plus keytruda® (pembrolizumab) combination treatment
- 07/19/2019
- latest trends of treatment for alzheimer’s disease in sessions and symposium at alzheimer’s association international conference (aaic) 2019
- 07/19/2019
- eisai presents data showing quantification of tau microtubule binding region in cerebrospinal fluid and the identification of a target engagement biomarker for the new anti-tau antibody e2814 at alzheimer’s association international conference (aaic)2019
